



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

MINUTES OF THE TEAMS MEETING 14th December 2022

PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Ms L Prince (LP)	Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GP Clinical Lead for Quality for Lancashire and South Cumbria ICS
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC

IN ATTENDANCE:

Mr Matthew Tattersall	Clinical Pharmacist, Pharmacy ELHT
Mr J D McCool	ELHT Dietetics
Mr John Eatough	Clinical Pharmacist, Pharmacy ELHT
Mr Ioannis Gkikas	Consultant gastroenterologist
Ms Fozia Shah	ELHT Diabetes

2022/189: APOLOGIES:

Mr Dominic Sebastian (DS)	Consultant Intensivist and Deputy DMD for SAS
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT

2022/190: DECLARATION OF INTEREST

SJ declared interest on item 2022/199 – Weight management pathways and semaglutide: approval could lead to an impact in Primary Care due to an increase in practice nurse/staff time for the extra appointments for injections that may be required.

2022/191: MINUTES OF OCTOBER TEAMS MEETING:

Amendment noted on page 2, 2nd line – should read £10,000

2022/192: MATTERS ARISING:

2021/101b: ELMMB Membership – to remain on action matrix as a standing item for feedback.



2022/156a: Formulary Updates: Gepan Instill: JV exploring possibility of Appliance Prescription Service prescribing the item. Agreed in principle but training will be required from urology and product to be added to Cobweb formulary.

ACTION: JV to bring back to Jan meeting

2022/156f: Valaciclovir 500mg tablets – agreed previously as second line choice after aciclovir for herpes simples. VG pointed out that there is a £10 cost difference per course of therapy between aciclovir and valaciclovir. VG has raised with microbiology and awaits a response. It was decided to look at prescribing data, remain on formulary, monitor prescribing trend and then review.

ACTION: Data to be obtained from epact and review in June 2023

2022/175: AEROTRACH PLUS Anti-static valved holding chamber – JV has spoken to the company. The product is non-drug tariff and currently only supplied to hospitals.MT to feed back to respiratory physicians and ENT teams.

Resolved

2022/176a: Melatonin – Request to review has been escalated back to LSCMMG by LR

2022/180: Expanded Access/Compassionate use schemes in Oncology – formal statement requested from Lancashire and South Cumbria Cancer Alliance to support decision to suspend the scheme. Nothing received this month.

ACTION: Deferred to February

2022/188: Octreotide – request by EoL consultants to include in new EoL service specification from April for bowel obstruction. This is currently RED Traffic Light on formulary and will need to switch to AMBER for this indication.

ACTION: Request to be sent to LSCMMG for review by LR

2022/193 New Product Request

Vagirux 10 micrograms vaginal tablets: Requested by obstetrics and gynaecology consultant for use in the treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women. The product can be used in women with or without a uterus and will replace vagifem® on formulary.

ACTION: agreed to add to formulary as GREEN traffic light, replacing vagifem®

2022/194 Formulary Updates

Emla cream: Request from obstetrics and gynaecology consultant to help with irritation symptoms in female patients using the product Aldara® for vulval intraepithelial neoplasia.

Traffic Light RED

Adcal D3 Dissolve 1500mg/400 unit effervescent tablets: To replace Calfovite D3 which has been discontinued. Prescribing reserved for patients with enteral feeding tubes (NGS/PEG etc) or patients with swallowing difficulties on a modified fluid/diet.

Traffic Light: GREEN



Trimbow® MDI: For maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year
Traffic Light: GREEN RESTRICTED

Hydrocortisone sodium phosphate eye drops (Softacort®): For the treatment of mild non-infective allergic or inflammatory conjunctival diseases. There is no significant difference in effectiveness compared to current formulary products and is not approved for use by the NHS in Lancashire and South Cumbria
Traffic Light: BLACK

RESOLVED: Formulary to be updated where appropriate

2022/195 LSCMMG Consultations –December 2022 [deadline 05/01/23]

- a. Degarelix: prostate cancer without spinal metastases (proposed Amber 0)
SJ raised point that NICE reflects that product should only be used with the available discount, and asked if this is available in primary care. NICE also says should only be used for treating advanced hormone-dependent prostate cancer in people with spinal metastases, but the position statement suggests a wider use. Also, Primary Care nurses will have to give monthly injections instead of 3 monthly leading to increased pressure on nurse time and workload. SJ also expressed concerns as to whether urology would be able to review patients on time due to workload.
- b. Oritavancin: treatment of acute, complicated bacterial skin and skin structure infections (proposed Red) – no comments
- c. Psoriasis Biologic Treatment Guideline – no comments
- d. Axial Spondyloarthritis pathway – no comments

For Action: Comments to be sent to LSCMMG

2022/196 LSCMMG Recommendations - November 2022

- a. Generic biosimilar medicines position statement - updated
- b. Nutritional supplement post-bariatric surgery position statement – updated
It was noted that the first page still says ‘NHS patients’, when it should read ‘patients’
ACTION: AB to feedback comment to LSCMMG
- c. Oral Nutritional Supplements Guideline
- d. Menopause Guideline

Resolved: items acknowledged by ELMMB. Website will be updated accordingly

2022/197 Pharmacy and Medicines Policy Task and Finish Group recommendations sheet (formally SCC) –November 2022

- a. Trimbow® MDI – maintenance treatment of asthma: **GREEN Restricted**
- b. Hydrocortisone sodium phosphate eye drops (Softacort®): **BLACK**

RESOLVED: Acknowledged by ELMMB.



2022/198 Other Items

Upadictinib financial arrangement for ulcerative colitis (pre-NICE TAG)
Deferred to next meeting

2022/199 Other Items

Weight management pathways and semaglutide:

There is currently no local access to weight management services in Pennine. The nearest Tier 4 service is in Aintree and Rochdale, but these are not funded to prescribe on an outpatient basis. Referrals currently go through ELHT community dietetics, but the process is complex and waiting times are long once approved. Since Aintree cannot initiate and support patients using semaglutide an increase in referrals for surgery have been noted by ELHT. There is a need for the issue to be raised with lead commissioners for them to incorporate into their pathways urgently before imminent NICE guidance. Semaglutide has been used in non-alcoholic fatty liver disease with good outcomes. Dr Gkikas, consultant gastroenterologist, has been able to treat diabetic patients with the disease using the support of the endocrine team, but is unable to offer treatment to non-diabetic patients. ELMMB members decided that a steering group would be set up. Referral of patients and liaison with diabetologists to continue until release of approved NICE guidance.

ACTION: LR to flag at next LSCMMG meeting.

2022/200 NICE Guidance – November 2022

None

2022/201 NICE Recommendations – November 2022

Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis- NICE TA838 (terminated appraisal) **Traffic Light: BLACK**

Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis - NICE TA839 (terminated appraisal) **Traffic Light: BLACK**

Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids - NICE TA840 (terminated appraisal) **Traffic Light: BLACK**

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma - NICE TA841(terminated appraisal)
Traffic Light: BLACK

Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies - NICE TA842 (terminated appraisal) **Traffic Light: BLACK**

Luspatercept for treating anaemia caused by beta-thalassaemia - NICE TA843 (terminated appraisal) **Traffic Light: BLACK**

Luspatercept for treating anaemia caused by myelodysplastic syndromes - NICE TA844(terminated appraisal) **Traffic Light: BLACK**



Mepolizumab for treating eosinophilic granulomatosis with polyangiitis - NICE TA845
(terminated appraisal) **Traffic Light: BLACK**

Mepolizumab for treating severe hypereosinophilic syndrome - NICE TA846 (terminated
appraisal) **Traffic Light: BLACK**

Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps - NICE TA847
(terminated appraisal) **Traffic Light: BLACK**

2022/202 NICE Highly Specialised Technologies –October 2022

None this month

2022/203 EAMS (Early access to medicines scheme) –October 2022

None this month

Standing Items:

**2022/204 For Action/Information: Lancashire & South Cumbria Medicines
Management Group (LSCMMG)**

DRAFT LSCMMG minutes 10th November 2022

Resolved: Minutes acknowledged.

**2022/205 For Action/Information: Lancashire & South Cumbria FT Drugs
and Therapeutics Committee**

Meeting took place Thursday 24th November 2022, minutes not yet available

2022/206 For Action/Information: Antimicrobial Stewardship Committee (ASC)

- a. ASC minutes 11th October 2022
- b. ASC action matrix 11th October 2022

**DATE OF NEXT MEETING – Wednesday 18th January 2023 12.30pm via ‘Microsoft
Teams’**



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 14th December 2022

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b	ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will required review as a result of that. Await full ICB structure	LR/VG	Jan 23
2022/156a	Formulary Updates: Gepan Instill JV to discuss possibility of prescribing being through Appliance Prescription Service	JV	Jan 23
2022/156f	Valaciclovir 500mg tablets To remain on formulary, monitor prescribing trend. To be reviewed in June 2023	LR/JV	Jun 23
2022/180	Other items: Expanded Access/Compassionate use schemes in Oncology HH to request formal position statement from Cancer Alliance	HH	Feb 23
2022/188	Octreotide: For use/inclusion on new EoL palliative care specification across Lancashire and South Cumbria ICS. Request to review to be submitted to LSCMMG	LR	Jan 23
2022/196	Nutritional supplement post-bariatric surgery position statement – updated Noted that the first page still says ‘NHS patients’, when it should read ‘patients’ AB to feedback comment to LSCMMG	AB	Jan 23
2022/198	Upadictinib financial arrangement for ulcerative colitis (pre-NICE TAG)	AB	Jan 23
2022/199	Weight management pathways and semaglutide LR to flag at next LSCMMG meeting	LR	Jan 23